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Abstract
Background: Endometrial cancer is the most common gynecologic malignancy in the developed countries. Clinical studies
have shown that early stage uterine serous carcinoma (USC) has outcomes similar to early stage high grade endometrioid
adenocarcinoma (EAC-G3) than to early stage low grade endometrioid adenocarcinoma (EAC-G1). However, little is known
about the origin of these different clinical outcomes. This study applied the whole genome expression profiling to explore
the expression difference of stage I USC (n=11) relative to stage I EAC-G3 (n=11) and stage I EAC-G1 (n=11), respectively.
Methodology/Principal Finding: We found that the expression difference between USC and EAC-G3, as measured by the
number of differentially expressed genes (DEGs), is consistently less than that found between USC and EAC-G1. Pathway
enrichment analyses suggested that DEGs specific to USC vs. EAC-G3 are enriched for genes involved in signaling
transduction, while DEGs specific to USC vs. EAC-G1 are enriched for genes involved in cell cycle. Gene expression
differences for selected DEGs are confirmed by quantitative RT-PCR with a high validation rate.
Conclusion: This data, although preliminary, indicates that stage I USC is genetically similar to stage I EAC-G3 compared to
stage I EAC-G1. DEGs identified from this study might provide an insight in to the potential mechanisms that influence the
clinical outcome differences between endometrial cancer subtypes. They might also have potential prognostic and
therapeutic impacts on patients diagnosed with uterine cancer.
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Introduction
Endometrial carcinoma is the most common gynecologic
malignancy in the United States [1]. Endometrioid adencoarci-
nomas (EAC) account for more than 80% of cases, and they tend
to present as low grade, early stage tumors with good outcomes.
While uterine serous carcinomas (USC) represent a minority (3–
10%) of total endometrial cancer cases, they are usually high grade
tumors with deep myometrial invasion, lymphovascular involve-
ment, and a more aggressive clinical course [2]. USC is
responsible for a disproportionate number of deaths reportedly
due to the fact that most of these tumors have already spread
outside the corpus. The 5-year survival rate for stage I-II EAC is
estimated to range between 75–87%, and between 44–50% for
stage I-II USC [3–5]. However, in EAC these outcomes vary with
FIGO (International Federation of Gynecology and Obstetrics)
tumor grade where five-year survival is 94% for FIGO grade 1
(EAC-G1) and 72% in high FIGO grade (EAC-G3) [6]. Several
reports have suggested that women with early stages USC and
clear cell carcinoma have a reasonably good 5- year disease free
survival rate of 72%, which was comparable to that of early stage
EAC- G3 tumors (76%) [7,8,9]. Furthermore, they even have
similar 5-year vaginal-pelvic control rate with 97% for the early
stages USC and clear cell carcinoma compared to 90% for early
stage EAC- G3 tumors.
Even though numerous studies have reviewed the clinical
outcomes of early stage USC when comparing EAC-G3 and EAC-
G1, the gene expression profiles defining these tumor subtypes and
the relations to their clinical behavior still remain unresolved. To
unravel this mystery, we performed a genome-wide expression
profiling analysis using the human Illumina bead microarray on 11
USC cases and compared them to 11 cases of stage I EAC-G3 and
11 cases of stage I EAC-G1, respectively. We found that the
expression difference between USC and EAC-G3, as measured by
the number of genes with significantly differential expression, is
consistently fewer than that found between USC and EAC-G1.
Pathway function annotation analyses suggested that the compo-
sition of enriched function terms was different among the two
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differences for selected DEGs were subsequently confirmed by
quantitative RT-PCR with a high validation rate. Our results,
while preliminary, suggest that the more similar clinical outcome
between stage I USC and stage I EAC-G3 potentially might be
related to their inherent genetic similarity.
Results
Analysis of Microarray data
We performed two separate comparisons; USC vs. EAC-G1
and USC vs. EAC-G3, respectively. Hierarchical clustering of
patients samples based on differentially expressed genes (DEGs)
showed that the obtained DEGs are able to classify patients into
their corresponding cancer subtype groups. As an example, the
clustering results for DEGs with p,0.01 and at least 1.5 fold
change are shown in Figure 1 (A: USC vs. EAC-G1; B: USC vs.
EAC-G3). The clear clustering results indicate that a direct
comparison of the lists of DEGs identified here might help to
explore the underlying mechanism accounting for clinical
outcome differences between USC vs. EAC-G1 and USC vs.
EAC-G3.
We found that the expression difference between USC and
EAC-G3, as quantified by the number of DEGs, was consistently
less than that between USC and EAC-G1 (Table 1 and
Figure 2). At a significance cutoff of p,0.01 with at least 1.5
fold change, the comparison between USC and EAC-G3 could
identify 667 DEGs (352 up-regulated and 315 down-regulated).
Using the same significance criteria, the comparison between USC
and EAC-G1 could identify 982 DEGs (398 up-regulated and 584
down-regulated). A total of 293 DEGs were shared by the two
comparisons, resulting in 374 genes specific to USC vs. EAC-G3
and 689 genes specific to USC vs. EAC-G1. Similar trends were
obtained when fold-change criteria was relaxed (i.e.,P ,0.01 only)
or more stringent (i.e.,P ,0.01 & at least two-fold changes). The
complete list of DEGs from the two separate comparisons
described above is listed in Table S2, S3.
Further functional enrichment analysis showed that the compo-
sition of enriched function terms was different between the DEGs
specific to USC vs. EAC-G1 and the DEGs specific to USC vs.
EAC-G3 (Figure 3). For the 374 DEGs specific to USC vs. EAC-
G3, the most enriched function terms are signal transduction, cell
communication and oncogenesis. Themostenriched function terms
for the 689 DEGs specific to USC vs. EAC-G1 arecell cycle,mitosis
and amino acid metabolism.Forthe rest of293 DEGs sharedby the
two comparisons, the enriched function terms include transport,
development process and neurogenesis. This suggests that different
pathways or different components of common pathways might
potentially account for the clinical outcome difference between
USC vs. EAC-G1 and USC vs. EAC. However, these results are
exploratory in nature and should be interpreted with cautions.
Future studies with a larger sample size followed by functional
experiments will be needed for validations.
P53 and PTEN signaling pathway
Previous studies have shown that aberrant P53 and/or PTEN
signaling pathways might play an important role in uterine and
endometrial cancer. Therefore, we tested the hypothesis whether
these two signaling pathway were significantly dysregulated in
each of the two comparisons we performed. Briefly, the 13,863
genes were ranked based on the level of expression fold change
(similar results are obtained based on t statistics score) for
comparing USC vs. EAC-G1 (or USC vs. EAC-G3). This ranked
list was used to analyze whether the fold change of genes for the
P53 (or PTEN) signaling pathway were significantly deviated from
those for the rest of genes. Statistical significance was estimated by
Kolmogorov–Smirnov test [10].
P53 gene was down-regulated (Fold Change=-1.63, P=2.99e-2)
in USC vs. EAC-G3 comparison, and P53 signaling pathway was
significantly down-regulated in USC vs. EAC-G3 comparison (K-S
Figure 1. Hierarchical clustering of patient samples based on differentially expressed genes with at least 1.5-fold change obtained
from USC versus EAC-G1 and USC versus EAC-G3, respectively. In clustering heat map, red means up-regulated while green means down
regulated. A) USC versus EAC-G1: In clustering dendrogram, blue stands for USC samples while yellow stands for EAC-G1 samples. B) USC versus EAC-
G3: In clustering dendrogram, blue stands for USC samples while yellow stands for EAC-G3 samples.
doi:10.1371/journal.pone.0018066.g001
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no change (Fold Change=21.01, P=0.97) in USC vs. EAC-G1
comparison, and P53 signaling pathway was not significantly
dysregulated in USC vs. EAC-G1 comparison (K-S Pvalue=0.11,
Figure 4b).
PTEN gene showed no change (Fold Change=1.05, P=0.74)i n
USC vs. EAC-G3 comparison, but are significantly up-regulated
(Fold Change=1.67, P=189e-3) in USC vs. EAC-G1 comparison.
However, PTEN signaling pathway was not found to be
significantly dysregulated in either USC vs. EAC-G3 comparison
(K-S Pvalue=0.45, Figure 4c) or USC vs. EAC-G1 comparison (K-S
Pvalue=0.16, Figure 4d).
Statistical estimation of false discovery rate
We used the approach of Benjamin and Hochberg [11] to
estimate false discovery rate for the derived DEG lists (at a
significance cutoff of p,0.01 with at least 1.5-fold change). For a
conservative estimation based on all 13,863 genes passing the
quality filter (i.e., controlling on 13,863 statistical tests), the
maximum FDR for the 667 DEGs derived from USC vs. EGC-G3
comparison is 9%, and the maximum FDR for the 982 DEGs
derived from USC vs. EGC-G1 comparison is 14%. Hence, the
FDR of both DEG sets are estimated to be ,15%.
As we only considered DEGs with at least 1.5-fold change for
further analysis, genes with less than 1.5-fold change can be
excluded before statistics testing. The number of genes with at
least 1.5-fold change is less than 1,750 for either USC vs. EGC-G3
or USC vs. EGC-G1 comparison. Controlled on the genes with at
least 1.5-fold change (i.e., applying fold-change analysis before
statistics tests), the maximum FDR for DEGs (p,0.01 &FC.1.5)
derived from USC vs. EGC-G3 comparison is 4.1%, and the
maximum FDR for DEGs (p,0.01 &FC.1.5) derived from USC
vs. EGC-G1 comparison is 2.5%.
Quantitative -RT-PCR validation of microarray data
We randomly selected 15 DEGs identified by microarray for
validation by quantitative Real Time PCR (qRT-PCR). According
to microarray analysis, all 15 selected genes are differentially
expressed in USC vs. EAC-G3 with at least 1.5 fold changes.
Selected genes include those up-regulated in USC vs. EAC-G3
(FBLN5, NES, SNCG, ACTN4, MSN, LMNA, TBX2, IRS2) and
those down-regulated in USC vs. EAC-G3 (CLDN7, EHF, NME5,
ALCAM, PHLDA1, CEACAM1, TFF3). qRT-PCR data of all 15
genes showed at least 1.5-fold change in expression levels in the
USC vs. EAC-G3 comparison and were concordant with the
microarray data, yielding a validation rate of 15/15 (Figure 5a–
b). Microarray analysis showed that 9 of the 15 selected genes are
also differentially expressed in USC vs. EAC-G1 comparison with
at least 1.5 fold changes. These 9 genes include those up-regulated
in USC vs. EAC-G1 (SNCG, MSN, LMNA, TBX2, IRS2), and those
down-regulated in USC vs. EAC-G1 (NME5, ALCAM, CEACAM1,
TFF3). For USC vs. EAC-G1, 7 of 9 genes showed at least 1.5-fold
changes in qRT-PCR estimated expression levels and were
concordant with the microarray data, yielding a validation rate
of 7/9 (Figure 5c–d). Even though MSN and TBX2 genes have less
than a 1.5-fold change in expression level based on qRT-PCR in
USC vs. EAC-G1 comparison, the direction (down or up-
regulated) of their expression estimated by qRT-PCR are
consistent with those estimated from microarray (Fig 5c–d).
Discussion
In this study, a genome-wide expression measurement was
performed using the human Illumina bead microarrays on 11
cases each of stage I USC, EAC-G3 and EAC-G1. We performed
two separate comparisons of USC vs. EAC-G1 and USC vs. EAC-
G3, respectively, to determine differentially expressed genes
(DEGs). A direct comparison of their gene expression patterns,
as quantified by the number and overlap of DEGs, was performed
Figure 2. Venn diagrams showing the number of differentially
expressed genes (DEGs) derived from USC vs. EAC-G3 com-
parison is consistently less than that derived from USC vs. EAC-
G1 comparison. A) DEGs as defined by P-value ,0.01. B) DEGs with at
least 1.5-fold change. C) DEGs with at least 2-fold change.
doi:10.1371/journal.pone.0018066.g002
Table 1. Summary of the number of differentially expressed
genes obtained from comparisons in USC vs. EAC-G1 and USC
vs. EAC-G3, respectively.
USC vs. EAC-G3 USC vs. EAC-G1 Overlap
P-value,0.01 988 1499 436
UP 509 639 211
Down 479 860 225
P-value,0.01 & 1.5 FC 667 982 293
UP 352 398 132
Down 315 584 161
P-value,0.01 & 2 FC 287 402 144
UP 142 137 52
Down 145 265 92
doi:10.1371/journal.pone.0018066.t001
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suggest that compared to USC vs. EAC-G1, USC vs. EAC-G3
was characterized by fewer DEGs, indicating that early stage USC
is genetically more similar to early stage EAC-G3 than to early
stage EAC-G1. Furthermore, we found that DEGs specific to USC
vs. EAC-G3 are enriched for genes involved in signal transduction,
while DEGs specific to USC vs. EAC-G1 are enriched for genes
involved in cell cycle.
The function of DEGs derived from this study may provide
insights into the molecular pathogenesis, and may explain the
highly aggressive behavior of USC. In addition, these DEGs, once
clinically verified in larger studies, may emerge as a potentially
useful diagnostic and therapeutic marker. We provided detailed
literature review about several DEGs observed in this study,
including SNCG, MSN and LMNA which are up-regulated in USC,
and ALCAM, NME5 and CEACAM1 which are down-regulated in
USC.
Synuclein-gamma (SNCG) gene (also known as breast cancer-
specific protein 1) was initially cloned from infiltrating breast
carcinoma cells [12]. This gene is located at the 10q23.2 locus and
highly expressed in several cancer types such as advanced stage of
ovarian, breast, liver, prostate and colon cancer [13,14]. Studies in
breast cancer showed its over-expression can stimulate cell
proliferation and induce invasion and metastasis [15]. Morgan
et al. showed that SNCG was over-expressed in a uterine serous
cancer cell line in comparison to endometrioid cancer cell line, and
knockdown of SNCG in serous cancer cell line caused a significant
decrease in cell proliferation and increased sensitivity to paclitaxel-
induced apoptosis [16]. The up-regulation of SNCG in our series of
USCpatientsamples reinforcesthat SNCGgene could be implicated
in the pathogenesis of uterine serous tumors. However, to confirm
SNCG as a prognostic marker and/or a therapeutic target in
patients with endometrial cancer, future studies with larger sample
size and functional experiments are needed.
MSN (membrane organizing extension spike protein) is closely
related to the EZR and RDX proteins [17]. All three proteins
constitute the ERM family which has been speculated to play a
specific role in the coordination of signals that are required for
tumor metastasis [18]. For example, MSN knockdown pancreatic
cancer cells showed increased migration, invasion, metastasis and
extracellular matrix organization [19], and EZR was found to be
involved in the process of invasion of endometrial cancer cells
[20,21]. The high level of MSN mRNA in our series of USC
samples suggests that it could have potential value as an indicator
for aggressive endometrial cancer phenotype. Additional studies
with larger group will be needed to evaluate its specific role.
Figure 3. Enriched function terms for differentially expressed genes (DEGs) with at least 1.5-fold change identified by microarray.
Function enrichment analyses are conducted using NCBI DAVID API server. The number following each enriched functional term is the number of
annotated DEGs. A) Enriched functional annotation for DEGs specific to USC vs. EAC-G1 comparison. B) Enriched functional annotation for DEGs
specific to USC vs. EAC-G3 comparison. C) Enriched functional annotation for DEGs shared by USC vs. EAC-G1 and USC vs. EAC-G3 comparison.
doi:10.1371/journal.pone.0018066.g003
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influences the activity of retinoblastoma protein and oncogenes
including b-catenin. Consequently, the expression of LMNA is
speculated to influence tumor progression [22]. LMNA was found
to be expressed in colon cancer and its expression level positively
associates with colon tumor progression and the risk of death
[23,24]. The role of LMNA up-regulation in our series of USC
remained to be explored in future study.
ALCAM (Activated leukocyte cell adhesion molecule) is
considered to be an important factor in epithelial cell integrity
whose alternation can lead to invasion and even metastasis [25].
Decreased ALCAM expression levels were associated with
aggressive behavior and poor outcome in several human tumors
including breast cancer, pancreatic cancer and ovarian carcinoma
[26,27,28]. The down-regulation of ALCAM in our series of USC
samples reinforces its potential role as a molecular predictor of
invasiveness and poor outcome in endometrial cancer patients.
NME5 (non-metastatic cells 5, protein expressed in (nucleoside-
diphosphate kinase)) gene is homologous to nm23-H1, a tumor
suppressor gene whose expression is often lost in urinary bladder
cancer and breast cancer [29,30]. Carcinoembryonic antigen-
related cell adhesion molecule1 (CEACAM1) has been reported to
be implicated in tumor suppression and cell migration of bladder
cancer [31,32]. The prognostic value of down-regulation of NME5
and CEACAM1 observed in our USC samples remain to be
established in future study.
One shortcoming of this study is the relatively small sample size
which does not provide us enough power for statistical analysis of
expression levels of DEGs and clinical characteristics. Our small-
size study is exploratory in nature and the data should be
interpreted with caution. Future large studies and functional
experiments are necessary to confirm our observations and further
explore the potential of DEGs to be utilized clinically as novel
biomarkers for endometrial cancer.
Materials and Methods
Tissue specimens
Flesh-frozen cancer specimens were obtained from 33 patients
undergoing surgery for uterine cancer at Roswell Park Cancer
Figure 4. Log2 fold change of microarray estimated expression for genes from an investigated pathway are plotted as a cumulative
distribution function (in red color) and compared with the corresponding cumulative distribution function for the rest of genes
(i.e., not belonging to the investigated pathway, in blue color). A) P53 signaling pathway in USC vs. EAC-G3 comparison. The two cumulative
distribution functions are significantly different (P=4.5e-3) by the Kolmogorov-Smirnov test. B) P53 signaling pathway in USC vs. EAC-G1 comparison.
C) PTEN signaling pathway in USC vs. EAC-G3 comparison. D) PTEN signaling pathway in USC vs. EAC-G1 comparison.
doi:10.1371/journal.pone.0018066.g004
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G3 and 11 cases of USC. All cases were stage I disease. All of the
tissue samples were collected under an Institutional Review Board-
approved protocol at RPCI. Specimens were collected after
written consent from the patient was obtained. The hematoxylin-
eosin (HE) slides were reviewed by an expert gynecologic
pathologist, to confirm the tumor subtype and FIGO grade. All
patients were treated per National Comprehensive Cancer
Network guidelines [33]. Patient charts were reviewed for
postoperative follow-up, which ranged from 18 to 60 months.
The detailed clinical and pathological information of patients are
shown in Table S1.
RNA preparation
The fresh frozen tissues were cut and examined to make certain
that the tissue contained .80% tumor. Total RNA from 10–
20 mg fresh frozen tissues were prepared using the RNeasy midi
kits (Qiagen, Valencia, CA) following manufacturer’s instructions.
Figure 5. qRT-PCR validations of selected differentially expressed genes with at least 1.5-fold expression change identified by
microarray. Blue bar is the fold change estimated by qRT-PCR, while red bar is the fold change estimated by microarray. The fold change is shown in
log2 scale. A–B) For USC vs. EAC-G3, 15 of 15 selected genes showed at least 1.5-fold change in qPCR estimated expression levels and was concordant
with the microarray data. C–D) For USC vs. EAC-G1, 7 of 9 selected genes showed at least 1.5-fold change in qPCR estimated expression levels and
was concordant with the microarray data. The two genes with less than 1.5-fold change in expression level based on qPCR are MXN and TBX2.
doi:10.1371/journal.pone.0018066.g005
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precipitation at 220uC overnight, and resuspended in nuclease-
free water. Before labeling, RNA samples were quantitated using a
ND-1000 spectrophotometer (NanoDrop Wilmington, DE) and
evaluated for degradation using a 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). Samples were required to have a
RIN.6.5, an OD 260:280 of 1.9–2.1, an OD 260/230 .1.5 and
.1.5 28S:18S ratio of the ribosomal bands for gene expression
array analysis.
Gene expression assay
Expressionprofiling wasaccomplished using the HumanHT-12 v3
whole-genome gene expression direct hybridization assay (Illumina,
San Diego, CA) as previously published [34]. Each array contains
full-length 50-mer probes representing more than 48,000 well-
annotated RefSeq transcripts, including .25,400 unique, curated,
and up-to-date genes derived from the National Center for
Biotechnology Information Reference Sequence (NCBI RefSeq)
database (Build 36.2, Release 22). Initially, 250 ng total RNA was
converted to cDNA, followed by an in vitro transcription step to
generate labeled cRNA using the Ambion Illumina Total Prep RNA
Amplification Kit (Ambion, Austin, TX) as per manufacturer’s
instructions. The labeled probes were then mixed with hybridization
reagents and hybridized overnight to the HumanHT-12 v3
BeadChips. Following washing and staining, the BeadChips were
imaged using the Illumina BeadArray Reader to measure fluores-
cence intensity at each probe. The intensity of the signal corresponds
to the quantity of the respective mRNA in the original sample. The
expression profiles have been deposited in NCBI’s Gene Expression
Omnibus (GEO) with GSE accession number GSE24537.
Data analysis
BeadChip data files are analyzed with Illumina’s GenomeStudio
gene expression module and R-based Bioconductor package to
determine gene expression signal levels [35]. Briefly, the raw
intensity of Illumina Human HT-12 v3.0 gene expression array was
scanned and extracted using BeadScan, with the data corrected by
background subtraction in GenomeStudio module. The lumi
module in the R-based Bioconductor Package was used to transform
the expression intensity into log2 scale [36]. The log2 transformed
intensity data were normalized using Quantile normalization
function. For data quality control, we only kept the genes whose
expression-detectionP-value was#0.05 (i.e.,distinguishable from the
background intensity) across .50% of samples in at least one group
(USC, EAC-G1 or EAC-G3). A total of 13,863 genes passed this
quality filtering for downstream analysis.
We then performed two separate comparisons for USC versus
EAC-G1 and USC versus EAC-G3, respectively. We used the
Limma program in the R-based Bioconductor package to calculate the
level of gene differential expression for each comparison [37].
Briefly, for each comparison, a linear model was fit to the data (with
cell means corresponding to the different cancer type and a random
effect for array). For each comparison, we obtained the list of
differentially expressed genes (DEGs) constrained by Pvalue,0.01.
Following single gene-based significance testing, we used the
expression value of DEGs (Pvalue,0.01) with at least 1.5-fold
change to cluster the patients. Our purpose was to determine
whether the identified DEGs were able to serve as a gene signature
to classify patients into their corresponding cancer type groups.
Hierarchical clustering algorithm based on the average linkage of
Pearson Correlation was employed [38]. The DEGs were
analyzed for enriched biological process terms using the NCBI
DAVID server (http://david.abcc.ncifcrf.gov) [39]. All calcula-
tions were carried out under R statistics computing.
Quantitative real time PCR analysis
The expression of 15 genes APLNR, CEBPA, CNTN1, ELF5,
EPHA1, FBLN1, FOSB, FST, HOXD10, KIF14, LMO4, LPAR2,
NME3, NR2F1, RASSF7, RHOBTB3, RPRM, TFF3 selected for
validation was determined using Taqman quantitative RT-PCR
(qRT-PCR) gene expression Assay On Demand Probe/Primers
(Applied Biosystems, Foster City, CA), with housekeeping gene
GAPDH as an endogenous control. Samples were run on the AB
HT7900 Sequence Detection System according to default
parameters, with three replicate assays for each gene in each
sample. Using the RQ Manager Software 2.2.2 (AB, Foster City,
CA) the data was analyzed with the baseline and the threshold
verified for each gene of interest. qRT-PCR data were the
normalized expression values in which the housekeeping gene
GAPDH was used as the reference gene. For each assay, the
average GAPDH Ct (Cycle threshold) value in the qPCR assay
was subtracted from the Ct of gene of interest to obtain a DCt
value (gene of interest - GAPDH).
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